Walleye Capital’s Nektar Therapeutics NKTR Stock Holding History

Walleye Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,878	Closed	-$927K	–	5038
2026 Q1	$927K	Buy	+12,878	New	+$733K	﹤0.01%	2143
2025 Q4	–	Sell	-36,107	Closed	-$2.05M	–	4957
2025 Q3	$2.05M	Buy	+36,107	New	+$1.2M	0.01%	1559
2023 Q2	–	Sell	-84,892	Closed	-$895K	–	4702
2023 Q1	$895K	Buy	84,892 +52,698	+164%	+$1.59M	0.01%	1242
2022 Q4	$1.09M	Buy	32,194 +611	+2%	+$29.6K	0.02%	948
2022 Q3	$1.52M	Sell	31,583 -865	-3%	-$51.5K	0.03%	700
2022 Q2	$1.85M	Buy	32,448 +7,468	+30%	+$471K	0.05%	386
2022 Q1	$2.02M	Buy	+24,980	New	+$3.7M	0.05%	375
2021 Q4	–	Sell	-872	Closed	-$235K	–	2246
2021 Q3	$235K	Buy	+872	New	+$210K	0.01%	1134
2021 Q1	–	Sell	-1,440	Closed	-$367K	–	1286
2020 Q4	$367K	Buy	+1,440	New	+$372K	0.02%	571

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's NKTR Position: Q2 2026 in Review

Walleye Capital sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 12,878 shares — an estimated $927K sold.

Walleye Capital first reported a position in NKTR in Q4 2020 and held it in 9 quarters. The position peaked at $2.05M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Walleye Capital reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 12,878 Nektar Therapeutics shares in Q2 2026, an estimated $927K.
Walleye Capital first reported a position in Nektar Therapeutics in Q4 2020 and held it in 9 quarters.
Walleye Capital's Nektar Therapeutics position peaked at $2.05M in Q3 2025.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.